Catheter Precision (VTAK) Expected to Post Earnings on Monday

Catheter Precision (NYSEAMERICAN:VTAK) is expected to be posting its results before the market opens on Monday, August 17th. Analysts expect the company to announce earnings of ($19.00) per share and revenue of $2.00 million for the quarter.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its quarterly earnings data on Monday, May 18th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($20.90) by $19.51. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%. The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $1.60 million.

Catheter Precision Price Performance

Shares of NYSEAMERICAN:VTAK opened at $0.28 on Monday. The firm has a market capitalization of $1.01 million, a PE ratio of -0.02 and a beta of -1.00. The business has a 50 day simple moving average of $0.74 and a two-hundred day simple moving average of $1.10. Catheter Precision has a 1 year low of $0.23 and a 1 year high of $4.31. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06.

Hedge Funds Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent quarter. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.